- Research
FAST-funded research is giving clinical trials a better way to capture how individuals living with Angelman syndrome communicate in everyday life. Research led by Bryce Reeve, PhD, and the Center
- Fundraising
When Michael and Ashley Scerbo learned that their daughter, Emma, had Angelman syndrome, they knew they wanted to do something to help advance research. They had never organized a fundraiser
- Industry
On October 8, 2026, ASF and FAST hosted a webinar with Ultragenyx after the announcement that their phase 3 trial for GTX-102 (aspire) did not meet primary or key secondary
- Fundraising
Before Sonia and her son José set off on Peru’s Inca Trail this September, their guides gave the group two goals: survive first, and finish if you can. For Sonia
- Industry
Read the press release
- Research
At INSYNC-AS 2026, researchers came together to examine how genes beyond UBE3A and differences within UBE3A itself may shape Angelman syndrome and future therapeutic development. Why can Angelman syndrome (AS)
- Industry
- Industry
Read the letter from Ultragenyx to the community: Angelman-Syndrome-Community-Update-9.16
- Industry
- Industry
Following the recent announcement on the outcome of the phase 3 Aspire trial of GTX-102, Oak Hill Bio has shared a message about their commitment to evaluate rugonersen in their
- Industry